Amniotic mesenchymal stem cells attenuate diabetic cardiomyopathy by inhibiting pyroptosis via modulation of the TLR4/NF-κb/NLRP3 pathway
Diabetic cardiomyopathy (DCM) is a specific type of cardiac dysfunction in diabetic patients, currently has no effective therapies. The TLR4 signaling pathway, activated through MyD88 and NF-κB, plays a critical role in DCM by triggering the release of pro-inflammatory cytokines and promoting pyropt...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Cell and Developmental Biology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2025.1631973/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849428220683747328 |
|---|---|
| author | Xuan Zhou Shaoliang Xing Lina Zhang Jungu Lu Deming Li Yating Wang Yuhang Ma Weiqin Chang Manman Su |
| author_facet | Xuan Zhou Shaoliang Xing Lina Zhang Jungu Lu Deming Li Yating Wang Yuhang Ma Weiqin Chang Manman Su |
| author_sort | Xuan Zhou |
| collection | DOAJ |
| description | Diabetic cardiomyopathy (DCM) is a specific type of cardiac dysfunction in diabetic patients, currently has no effective therapies. The TLR4 signaling pathway, activated through MyD88 and NF-κB, plays a critical role in DCM by triggering the release of pro-inflammatory cytokines and promoting pyroptosis through NLRP3 inflammasomes. Additionally, the TGF-β/Smad signaling pathway drives myocardial fibrosis, further compromising cardiac function. Recently, amniotic mesenchymal stem cells (AMSCs) have emerged as a promising therapeutic option due to their ease of access, low immunogenicity, and ability to differentiate into multiple cell types. In this study, a DCM mouse model was treated with AMSCs via tail vein injection every 2 weeks for four doses. Evaluations included glucose tolerance tests, echocardiography, serum analysis, and histopathological and molecular assessments. Results showed AMSCs improved pancreatic function, reduced blood glucose, and enhanced insulin secretion. Cardiac function and morphology improved, with reduced inflammation. Molecularly, AMSCs inhibited pyroptosis via TLR4/NF-κB/NLRP3 pathway suppression and reduced fibrosis through TGF-β/Smad modulation. These findings indicate AMSCs alleviate DCM cardiac dysfunction and pyroptosis, primarily by inhibiting the TLR4/NF-κB/NLRP3 pathway. The study underscores AMSCs as a promising therapeutic strategy for DCM, warranting further clinical exploration. |
| format | Article |
| id | doaj-art-518ffcaada4c4991bc44d0db086fd1ad |
| institution | Kabale University |
| issn | 2296-634X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cell and Developmental Biology |
| spelling | doaj-art-518ffcaada4c4991bc44d0db086fd1ad2025-08-20T03:28:47ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2025-07-011310.3389/fcell.2025.16319731631973Amniotic mesenchymal stem cells attenuate diabetic cardiomyopathy by inhibiting pyroptosis via modulation of the TLR4/NF-κb/NLRP3 pathwayXuan Zhou0Shaoliang Xing1Lina Zhang2Jungu Lu3Deming Li4Yating Wang5Yuhang Ma6Weiqin Chang7Manman Su8Department of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun, ChinaNMPA Key Laboratory for Quality Control of Cell and Gene Therapy Medicine Products Northeast Normal University, Changchun, ChinaNMPA Key Laboratory for Quality Control of Cell and Gene Therapy Medicine Products Northeast Normal University, Changchun, ChinaDepartment of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun, ChinaDepartment of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun, ChinaDepartment of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun, ChinaDepartment of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun, ChinaThe Second Clinical Hospital, Jilin University, Changchun, ChinaDepartment of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun, ChinaDiabetic cardiomyopathy (DCM) is a specific type of cardiac dysfunction in diabetic patients, currently has no effective therapies. The TLR4 signaling pathway, activated through MyD88 and NF-κB, plays a critical role in DCM by triggering the release of pro-inflammatory cytokines and promoting pyroptosis through NLRP3 inflammasomes. Additionally, the TGF-β/Smad signaling pathway drives myocardial fibrosis, further compromising cardiac function. Recently, amniotic mesenchymal stem cells (AMSCs) have emerged as a promising therapeutic option due to their ease of access, low immunogenicity, and ability to differentiate into multiple cell types. In this study, a DCM mouse model was treated with AMSCs via tail vein injection every 2 weeks for four doses. Evaluations included glucose tolerance tests, echocardiography, serum analysis, and histopathological and molecular assessments. Results showed AMSCs improved pancreatic function, reduced blood glucose, and enhanced insulin secretion. Cardiac function and morphology improved, with reduced inflammation. Molecularly, AMSCs inhibited pyroptosis via TLR4/NF-κB/NLRP3 pathway suppression and reduced fibrosis through TGF-β/Smad modulation. These findings indicate AMSCs alleviate DCM cardiac dysfunction and pyroptosis, primarily by inhibiting the TLR4/NF-κB/NLRP3 pathway. The study underscores AMSCs as a promising therapeutic strategy for DCM, warranting further clinical exploration.https://www.frontiersin.org/articles/10.3389/fcell.2025.1631973/fulldiabetic cardiomyopathytype 2 diabetes mellitusamniotic mesenchymal stem cellsfibrosispyroptosis |
| spellingShingle | Xuan Zhou Shaoliang Xing Lina Zhang Jungu Lu Deming Li Yating Wang Yuhang Ma Weiqin Chang Manman Su Amniotic mesenchymal stem cells attenuate diabetic cardiomyopathy by inhibiting pyroptosis via modulation of the TLR4/NF-κb/NLRP3 pathway Frontiers in Cell and Developmental Biology diabetic cardiomyopathy type 2 diabetes mellitus amniotic mesenchymal stem cells fibrosis pyroptosis |
| title | Amniotic mesenchymal stem cells attenuate diabetic cardiomyopathy by inhibiting pyroptosis via modulation of the TLR4/NF-κb/NLRP3 pathway |
| title_full | Amniotic mesenchymal stem cells attenuate diabetic cardiomyopathy by inhibiting pyroptosis via modulation of the TLR4/NF-κb/NLRP3 pathway |
| title_fullStr | Amniotic mesenchymal stem cells attenuate diabetic cardiomyopathy by inhibiting pyroptosis via modulation of the TLR4/NF-κb/NLRP3 pathway |
| title_full_unstemmed | Amniotic mesenchymal stem cells attenuate diabetic cardiomyopathy by inhibiting pyroptosis via modulation of the TLR4/NF-κb/NLRP3 pathway |
| title_short | Amniotic mesenchymal stem cells attenuate diabetic cardiomyopathy by inhibiting pyroptosis via modulation of the TLR4/NF-κb/NLRP3 pathway |
| title_sort | amniotic mesenchymal stem cells attenuate diabetic cardiomyopathy by inhibiting pyroptosis via modulation of the tlr4 nf κb nlrp3 pathway |
| topic | diabetic cardiomyopathy type 2 diabetes mellitus amniotic mesenchymal stem cells fibrosis pyroptosis |
| url | https://www.frontiersin.org/articles/10.3389/fcell.2025.1631973/full |
| work_keys_str_mv | AT xuanzhou amnioticmesenchymalstemcellsattenuatediabeticcardiomyopathybyinhibitingpyroptosisviamodulationofthetlr4nfkbnlrp3pathway AT shaoliangxing amnioticmesenchymalstemcellsattenuatediabeticcardiomyopathybyinhibitingpyroptosisviamodulationofthetlr4nfkbnlrp3pathway AT linazhang amnioticmesenchymalstemcellsattenuatediabeticcardiomyopathybyinhibitingpyroptosisviamodulationofthetlr4nfkbnlrp3pathway AT jungulu amnioticmesenchymalstemcellsattenuatediabeticcardiomyopathybyinhibitingpyroptosisviamodulationofthetlr4nfkbnlrp3pathway AT demingli amnioticmesenchymalstemcellsattenuatediabeticcardiomyopathybyinhibitingpyroptosisviamodulationofthetlr4nfkbnlrp3pathway AT yatingwang amnioticmesenchymalstemcellsattenuatediabeticcardiomyopathybyinhibitingpyroptosisviamodulationofthetlr4nfkbnlrp3pathway AT yuhangma amnioticmesenchymalstemcellsattenuatediabeticcardiomyopathybyinhibitingpyroptosisviamodulationofthetlr4nfkbnlrp3pathway AT weiqinchang amnioticmesenchymalstemcellsattenuatediabeticcardiomyopathybyinhibitingpyroptosisviamodulationofthetlr4nfkbnlrp3pathway AT manmansu amnioticmesenchymalstemcellsattenuatediabeticcardiomyopathybyinhibitingpyroptosisviamodulationofthetlr4nfkbnlrp3pathway |